United Therapeutics (UTHR) Tops Q1 EPS by 19c, Miss on Revenues
United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $3.76, $0.19 better than the analyst estimate of $3.57. Revenue for the quarter came in at $389.2 million versus the consensus estimate of $401.94 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
